Bioniche to offer 20 million shares

Bioniche Life Sciences (TSX:BNC) is offering up to 20 million new common shares in two concurrent financings by short-form prospectus in all provinces of Canada and by initial public offering in Australia and New Zealand. Stock may be offered in other jurisdictions on a private placement basis. The Canadian sale is being underwritten by a [...]

Bioniche receives Urocidin payment from Endo

Bioniche Life Sciences (TSX:BNC) has achieved a $4 million (U.S.) milestone payment from its development partner, Endo Pharmaceuticals (NASDAQ:ENDP), its fourth since July, 2009. The current milestone payment was triggered by Bioniche’s Urocidin drug attaining a “contractual efficacy goal” from an ongoing FDA Phase 3 registration trial as a treatment for non-muscle-invasive bladder cancer. Bioniche [...]

Bioniche links future disclosure to trading activity

Bioniche Life Sciences (TSX:BNC) expects to make a statement within the next several weeks about its Phase 3 clinical trial with its bladder cancer drug Urocidin. The company made the disclosure in response to recent activity in shares, noting that it believes the jump in volume and share price was driven by expectations of a statement [...]

Bioniche licenses botanicals from University of Ottawa

Bioniche Life Sciences (TSX:BNC) and the University of Ottawa have signed an exclusive global licence agreement that gives Bioniche commercial access to the university’s technology for natural health botanical therapeutics and pharmaceutical compounds for treating anxiety and related conditions in animals, humans and aquaculture. University of Ottawa researchers and collaborators at the Universidad Nacional in Costa [...]

Bioniche-Endo set for additional Phase 3 trial

Bioniche Life Sciences (TSX:BNC) and its development partner, Endo Pharmaceuticals (NASDAQ: ENDP), are in the process of finalizing a protocol for an additional Phase 3 clinical trial of their Urocidin bladder cancer drug, which is expected to begin enrolling patients in 2010. “We’re preparing to initiate a large study with Urocidin in the second half [...]

Bioniche shares jump 34% on Endo taking up global rights

Shares of Bioniche Life Sciences touched a 52-week high on the Toronto Stock Exchange Friday after marketing partner Endo Pharmaceuticals elected to exercise its option for exclusive global rights to develop and market Bioniche’s non-muscle-invasive bladder cancer product. As a result, Endo (NASDAQ:ENDP) will all assume all external development expenses for the product, Bioniche (TSX:BNC) [...]